<DOC>
	<DOCNO>NCT01806610</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , PK follow single administration BPS804 patient chronic kidney disease stage 5D ( CKD-5D ) hemodialysis .</brief_summary>
	<brief_title>Study Safety Tolerability BPS804 Patients With Late-stage Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion criterion Written inform consent must obtain assessment perform . Males female age 18 80 year include , CKD5D ( GFR &lt; 15 mL/min per 1.73m2 ) stable hemodialysis evidence monthly Kt/Vurea ≥ 1.20 ( obtain local laboratory ) urea reduction ratio ≥ 60 % ( obtained local laboratory ) past 3 consecutive month prior screen . Patient must maintenance renal replacement therapy ( i.e. , exclusively standard hemodialysis nonporous membrane ) 3 time per week , &gt; 3 month screen stable dialysis prescription , define change material ( i.e. , dialyzer , filter/ membrane ) type dialysis duration ≥ 4 week screen . If patient currently treat calcimimetics , prescribe dose must constant least 30 day prior screen remain constant study duration . If patient currently treat vitamin D , prescribe dose must constant least 30 day prior screen remain constant study duration . Screening body mass index ( BMI ) &gt; 18.5 ≤ 35 kg/m2 weigh least 50 kg . Able communicate well investigator , understand comply requirement study . Exclusion Criteria Patients peritoneal dialysis . Patients parathyroidectomy within 3 month prior screen patient parathyroidectomy schedule course study . Patients kidney transplant schedule study . Patients clinically symptomatic spinal stenosis . Women pregnant nursing ( lactate ) . Women childbearing potential planning pregnancy course duration study . Women childbearing potential , defined woman physiologically capable become pregnant , must use highly effective contraception study 5 halflives ( i.e. , around 10 week ) stop treatment . Highly effective contraception define either : 1 . Total abstinence : When line prefer usual lifestyle patient . [ Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] . 2 . Sterilization : surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . 3 . Male partner sterilization ( appropriate postvasectomy documentation absence sperm ejaculate ) . [ For female study patient , vasectomised male partner sole partner patient ] . 4 . Use combination two follow ( 1+2 1+3 2+3 ) : 1 . Use oral , injected implant hormonal method contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . In case use oral contraception woman stable pill minimum 3 month take study treatment . Liver disease liver injury indicate abnormal liver function test SGOT ( AST ) , SGPT ( ALT ) , γGT . Hemoglobin ≤ 9 g/dL male , ≤ 8 g/dL female patient . ( Note : Treatment erythropoietinstimulating agent ( ESA ) allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled trial</keyword>
	<keyword>BPS804</keyword>
	<keyword>Safety , tolerability , PK</keyword>
	<keyword>Patients late-stage chronic kidney disease .</keyword>
</DOC>